Better Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Better Therapeutics

24/03/2023 20:55

* Better Therapeutics Inc  BTTX.OQ   BTTX.O  is expected
to show
no change in quarterly revenue when it reports  results on March
30. 
    * 
    * ​Refinitiv's mean analyst estimate for Better Therapeutics
Inc
is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Better
Therapeutics Inc is $15​, above​ its last closing price
of $0.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.44       -0.48      -0.48     Met     -0.7
 Jun. 30 2022  -0.46       -0.45      -0.42     Beat    6.7
 Mar. 31 2022  -0.40       -0.38      -0.41     Missed  -6.5​
 Dec. 31 2021  -0.47       -0.46      -0.71     Missed  -55.5
 ​​Sep.        -1.66       -1.66      -0.03     Beat    98.2
 30 2021                                                
                                                        ​
 This summary was machine generated March 24 at 20:55 GMT.  All
figures in US dollars  unless otherwise stated